20 August 2024 in Magnetic Resonance in Medicine
Purpose: Quantitative MRI enables direct quantification of contrast agent concentrations in contrast‐enhanced scans. However, the lengthy scan times required by conventional methods are inadequate for tracking contrast agent transport dynamically in mouse brain. We developed a 3D MR fingerprinting (MRF) method for simultaneous T1 and T2 mapping across the whole mouse brain with 4.3‐min temporal resolution.Method: We designed a 3D MRF sequence with variable acquisition segment lengths and magnetization preparations on a 9.4T preclinical MRI scanner. Model‐based reconstruction approaches were employed to improve the accuracy and speed of MRF acquisition. The method's accuracy for T1 and T2 measurements was validated in vitro, while its repeatability of T1 and T2 measurements was evaluated in vivo (n = 3). The utility of the 3D MRF sequence for dynamic tracking of intracisternally infused gadolinium‐diethylenetriamine pentaacetic acid (Gd‐DTPA) in the whole mouse brain was demonstrated (n = 5).Results: Phantom studies confirmed accurate T1 and T2 measurements by 3D MRF with an undersampling factor of up to 48. Dynamic contrast‐enhanced MRF scans achieved a spatial resolution of 192 × 192 × 500 μm3 and a temporal resolution of 4.3 min, allowing for the analysis and comparison of dynamic changes in concentration and transport kinetics of intracisternally infused Gd‐DTPA across brain regions. The sequence also enabled highly repeatable, high‐resolution T1 and T2 mapping of the whole mouse brain (192 × 192 × 250 μm3) in 30 min.Conclusion: We present the first dynamic and multi‐parametric approach for quantitatively tracking contrast agent transport in the mouse brain using 3D MRF.
13 August 2025 in Magnetic Resonance in Medicine
Purpose: The clinical utility of conventional DCE‐MRI methods is limited by the use of conventional qualitative dynamic T1‐weighted images, resulting in poor reproducibility. This study presents the initial implementation of a new DCE‐magnetic resonance fingerprinting (DCE‐MRF) methodology to provide reproducible, quantitative assessments of tumor vascular perfusion.Methods: The DCE‐MRF acquisition combines multiple T1 preparations, highly undersampled spiral trajectories (R = 48), a low‐rank reconstruction method, and low tip angles on a 9.4 T preclinical MRI scanner to rapidly generate dynamic T1 maps (23‐s temporal resolution). In vitro validation experiments were conducted across a range of Gadovist concentrations to assess accuracy and temporal precision in comparison to conventional methods. The DCE‐MRF method was also evaluated in vivo in an orthotopic 4T1 mouse model of breast cancer (n = 25). Pharmacokinetic modeling of the in vivo data was performed using a linear reference region model (LRRM).Results: In vitro DCE‐MRF studies demonstrated good agreement with conventional MRI methods for T1 measurements (R2 0.99). The iterative low‐rank reconstruction method also reduced artifacts compared to conventional reconstruction methods. DCE‐MRF demonstrated a 2‐ to 3‐fold reduction in temporal variability compared to conventional DCE‐MRI, and enabled effective in vivo pharmacokinetic modeling using the LRRM by generating voxelwise maps of RKtrans and kep,T as measures of tumor vascular perfusion.Conclusions: DCE‐MRF represents a new inherently quantitative approach to measuring tumor vascular perfusion that can be used in animal models and eventually in patients.
12 September 2024 in Kidney International Reports
1 February 2026 in Magnetic Resonance in Medicine
Purpose: Dynamic contrast‐enhanced MRI (DCE‐MRI) can assess tumor perfusion using pharmacokinetic models. However, poor DCE‐MRI reproducibility from reliance on conventional T 1 ‐weighted MRI has limited clinical translation. We evaluated whether Dynamic Contrast Enhanced‐Magnetic Resonance Fingerprinting (DCE‐MRF), which directly generates quantitative T 1 relaxation time constant maps, provides improved precision and statistical power for detecting treatment‐induced vascular changes compared to conventional DCE‐MRI. Methods: Twenty female mice bearing orthotopic 4 T1 breast tumors were randomly assigned to DCE‐MRF ( n = 12) or conventional DCE‐MRI ( n = 8) cohorts. Both methods acquired matched spatial and temporal resolution (23‐s) T 1 measurements at baseline, 3 h, and 48 h post‐treatment with combretastatin A4 phosphate (120 mg/kg), a known vascular disrupting agent. Perfusion assessments were obtained with a pharmacokinetic Linear Reference Region Model ( RK trans and k ep,T ) and model‐independent initial area under the curve assessments and compared using Wilcoxon signed‐rank tests and Hedges' g effect sizes. Results: DCE‐MRF demonstrated 1.3‐to‐5.1‐fold larger effect sizes for RK trans across all regions and timepoint comparisons, and 1.3‐to‐1.9‐fold larger effect sizes for tumor rim k ep,T compared to conventional DCE‐MRI. RK trans and k ep,T at 3 h post‐treatment in all regions, detected significant vascular recovery for whole tumor RK trans and both whole tuomor and tumor rim for k ep,T at 48 h, whereas DCE‐MRI only detected significant changes at 3 h. Conclusions: DCE‐MRF's improved measurement precision and increased effect size translates directly to enhanced statistical power for detecting treatment‐induced vascular changes, positioning it as a more reproducible tumor perfusion assessment for animal models and eventually cancer patients.
1 March 2026 in Radiology
Kidney T1 and T2 relaxation times extracted from MR fingerprinting provided complementary information for noninvasive differentiation of indolent versus aggressive renal neoplasms.